Nimodipine is a small molecule commercialized by Acasti Pharma, with a leading Phase III program in Subarachnoid Hemorrhage. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Nimodipine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The revenue for Nimodipine is expected to reach an annual total of $56 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Nimodipine Overview

Nimodipine (GTX-104) is under development for the treatment of aneurysmal subarachnoid hemorrhage (aSAH). The drug candidate is formulated as nanoparticle solution administered through intravenous route. Nimodipine acts by targeting the L-type calcium channel (Subunit Alpha 1F, Subunit Alpha 1D, Subunit Alpha 1C, Subunit Alpha 1S).

See Also:

Acasti Pharma Overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Acasti Pharma (Acasti), subsidiary of Neptune Technologies & Bioressources Inc, is a biopharmaceutical company that conducts research, development, and commercialization of krill oil-based forms of omega-3 fatty acids. The company develops phospholipid therapies for abnormalities in blood lipids, and treatment and prevention of various cardiometabolic disorders. Its product include CaPre, a drug product candidate, used for the treatment of hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream and Onemia, a medical food that is used in the dietary management of diseases associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Acasti is headquartered in Laval, Quebec, Canada.
The operating loss of the company was US$52.2 million in FY2023, compared to an operating loss of US$15.6 million in FY2022. The net loss of the company was US$42.4 million in FY2023, compared to a net loss of US$9.8 million in FY2022.

For a complete picture of Nimodipine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.